{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:18:01Z","timestamp":1772183881768,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.3816\/clml.2010.n.055","type":"journal-article","created":{"date-parts":[[2010,8,14]],"date-time":"2010-08-14T06:11:22Z","timestamp":1281766282000},"page":"262-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma"],"prefix":"10.3816","volume":"10","author":[{"given":"Julie","family":"Lignon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sibon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Madelaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josette","family":"Briere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Mounier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Faure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.055_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.055_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.055_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.055_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/bjc.1993.393","article-title":"EPIC: an effective low toxicity regimen for relapsing lymphoma","volume":"68","author":"Hickish","year":"1993","journal-title":"Br J Cancer"},{"key":"10.3816\/CLML.2010.n.055_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00277-006-0243-9","article-title":"Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients","volume":"86","author":"Aydin","year":"2007","journal-title":"Ann Hematol"},{"key":"10.3816\/CLML.2010.n.055_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11912-009-0052-0","article-title":"Second-line treatment paradigms for diffuse large B-cell lymphomas","volume":"11","author":"Thieblemont","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"10.3816\/CLML.2010.n.055_bib7","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.055_bib8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/oxfordjournals.annonc.a010500","article-title":"Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer","volume":"7","author":"Chollet","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.055_bib9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0959-8049(98)00007-0","article-title":"Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques","volume":"34","author":"Monnet","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLML.2010.n.055_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.annonc.a010489","article-title":"Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines","volume":"7","author":"Machover","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.055_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/A:1008310708853","article-title":"Preliminary results on the activity of oxaliplatin (L-OHP) in refractory\/recurrent non-Hodgkin's lymphoma patients","volume":"10","author":"Germann","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.055_bib12","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2001.03181.x","article-title":"An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma","volume":"115","author":"Chau","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.055_bib13","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1023\/A:1012501305214","article-title":"Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma","volume":"12","author":"Machover","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.055_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-008-0847-y","article-title":"A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory\/relapsed aggressive non-Hodgkin's lymphoma","volume":"64","author":"Sym","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CLML.2010.n.055_bib15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.1323.1323","article-title":"R-DHAOX as salvage regimen in patients (PTs) with relapsed\/resistant non-Hodgkin's lymphoma (NHL)","volume":"104","author":"Rupolo","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.055_bib16","first-page":"25","article-title":"Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine","volume":"41","author":"Bergerat","year":"1981","journal-title":"Cancer Res"},{"key":"10.3816\/CLML.2010.n.055_bib17","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.3816\/CLML.2010.n.055_bib18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.055_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","article-title":"Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial","volume":"111","author":"Vellenga","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.055_bib20","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1080\/10428190600926572","article-title":"DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis","volume":"47","author":"Mey","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLML.2010.n.055_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.4601.4601","article-title":"ESHAP+\/\u2013 rituximab as salvage therapy for relapsed lymphoma prior to stem cell transplant: single institution experience","volume":"104","author":"Shrestha","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.055_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.4636.4636","article-title":"Rituximab (Rituxan) combined with ESHAP chemotherapy is highly active in relapsed\/refractory aggressive non-Hodgkin's lymphoma","volume":"104","author":"Venugopal","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.055_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.3067.3067","article-title":"Rituximab increases response to ESHAP in relapsed, refractory, and transformed aggressive B-cell lymphoma","volume":"108","author":"Hicks","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.055_bib24","article-title":"Rituximab-ESHAP as salvage therapy in relapsed aggressive B cell lymphoma","volume":"90","author":"Arnold","year":"2005","journal-title":"Haematologica"},{"issue":"suppl","key":"10.3816\/CLML.2010.n.055_bib25","first-page":"15s","article-title":"R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study","volume":"27","author":"Gisselbrecht","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.055_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","article-title":"Cisplatin nephrotoxicity: a review","volume":"334","author":"Yao","year":"2007","journal-title":"Am J Med Sci"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:33Z","timestamp":1761870153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S2152265011700325"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.055","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}